Literature DB >> 18052336

Establishment of higher passage PER.C6 cells for adenovirus manufacture.

Marina Berdichevsky1, Marie-Pierre Gentile, Benjamin Hughes, Peter Meis, Joseph Peltier, Ilse Blumentals, John Auniņs, Nedim Emil Altaras.   

Abstract

PER.C6 cells, an industrially relevant cell line for adenovirus manufacture, were extensively passaged in serum-free suspension cell culture to better adapt them to process conditions. The changes in cell physiology that occurred during this passaging were characterized by investigating cell growth, cell size, metabolism, and cultivation of replication-deficient adenovirus. The changes in cell physiology occurred gradually as the population doubling level, the number of times the cell population had doubled, increased. Higher passage PER.C6 (HP PER.C6) proliferated at a specific growth rate of 0.043 h(-1), 2-fold faster than lower passage PER.C6, and were capable of proliferation from lower inoculation cell densities. HP PER.C6 cell volume was 16% greater, and cellular yields on glucose, lactate, oxygen, and amino acids were greater as well. In batch cultures, HP PER.C6 cells volumetrically produced 3-fold more adenovirus, confirmed with three different constructs. The increase in productivity was also seen on a cell-specific basis. Although HP PER.C6 were more sensitive to the "cell density effect", requiring lower infection cell densities for optimal specific productivity, they proliferated more after infection than lower passage PER.C6, increasing the number of cells available for virus production. The extensive passaging established HP PER.C6 cells with several desirable attributes for adenovirus manufacture.

Entities:  

Mesh:

Year:  2007        PMID: 18052336     DOI: 10.1021/bp070258u

Source DB:  PubMed          Journal:  Biotechnol Prog        ISSN: 1520-6033


  2 in total

1.  On-line monitoring of responses to nutrient feed additions by multi-frequency permittivity measurements in fed-batch cultivations of CHO cells.

Authors:  Sven Ansorge; Geoffrey Esteban; Georg Schmid
Journal:  Cytotechnology       Date:  2010-04-21       Impact factor: 2.058

2.  An adenovirus-vectored nasal vaccine confers rapid and sustained protection against anthrax in a single-dose regimen.

Authors:  Jianfeng Zhang; Edward Jex; Tsungwei Feng; Gloria S Sivko; Leslie W Baillie; Stanley Goldman; Kent R Van Kampen; De-chu C Tang
Journal:  Clin Vaccine Immunol       Date:  2012-10-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.